Spruce Biosciences, Inc.
SPRBHealthcare|Biotechnology|US
$46.55
+3.84 (+8.99%)
DCF Value
$61.82
Tangible Book / Share
$34.44
Cash / Share
$39.61
Clinical Trials (8)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT07579910 Intracerebroventricular Tralesinidase Alfa in Participants With MPS IIIB (Sanfilippo Syndrome Type B) | MPS IIIB | P3 | Not Yet Recruiting | 14 | RCT, Single-blind | Tralesinidase alfa (TA) |
| NCT03687242 Study to Evaluate the Safety and Efficacy of SPR001 in Subjects With Classic Congenital Adrenal Hyperplasia | Congenital Adrenal Hyperplasia, CAH - Congenital Adrenal Hyperplasia | P2 | Completed | 11 | Open-label | SPR001 |
| NCT03257462 Study of SPR001 in Adults With Classic Congenital Adrenal Hyperplasia | Congenital Adrenal Hyperplasia, CAH - Congenital Adrenal Hyperplasia | P2 | Completed | 24 | Open-label | SPR001 |
| NCT05370521 A Study of Safety and Efficacy of Tildacerfont in Females With Polycystic Ovary Syndrome and Elevated Adrenal Androgens | Polycystic Ovary Syndrome | P2 | Terminated | 27 | RCT, Double-blind | Tildacerfont, Placebo |
| NCT05128942 A Phase 2 Study to Evaluate the Safety, Efficacy and PK of Tildacerfont in Children Aged 2-17 Years With CAH | Congenital Adrenal Hyperplasia, 21-OHD | P2 | Terminated | 67 | Open-label | Tildacerfont |
| NCT04457336 A Ph2b to Evaluate Clinical Efficacy and Safety of Tildacerfont in Adult CAH | Congenital Adrenal Hyperplasia | P2 | Terminated | 96 | RCT, Double-blind | Tildacerfont/Placebo |
| NCT04544410 A Ph2b to Evaluate Tildacerfont in the Reduction of Glucocorticoid Steroid Doses in Adult CAH | Congenital Adrenal Hyperplasia | P2 | Terminated | 100 | RCT, Double-blind | Tildacerfont/Placebo |
| NCT07733856 Early Access Treatment With Tralesinidase Alfa in Mucopolysaccharidosis Type IIIB (Sanfilippo Syndrome Type B) | Mucopolysaccharidosis Type IIIB, MPS IIIB (Sanfilippo B Syndrome) | AVAILABLE | — | — | Tralesinidase alfa (TA) |